Transposon clusters as substrates for aberrant splice-site activation - PubMed
Transposon clusters as substrates for aberrant splice-site activation
Maria Elena Vilar Alvarez et al. RNA Biol. 2021 Mar.
Abstract
Transposed elements (TEs) have dramatically shaped evolution of the exon-intron structure and significantly contributed to morbidity, but how recent TE invasions into older TEs cooperate in generating new coding sequences is poorly understood. Employing an updated repository of new exon-intron boundaries induced by pathogenic mutations, termed DBASS, here we identify novel TE clusters that facilitated exon selection. To explore the extent to which such TE exons maintain RNA secondary structure of their progenitors, we carried out structural studies with a composite exon that was derived from a long terminal repeat (LTR78) and AluJ and was activated by a C > T mutation optimizing the 5' splice site. Using a combination of SHAPE, DMS and enzymatic probing, we show that the disease-causing mutation disrupted a conserved AluJ stem that evolved from helix 3.3 (or 5b) of 7SL RNA, liberating a primordial GC 5' splice site from the paired conformation for interactions with the spliceosome. The mutation also reduced flexibility of conserved residues in adjacent exon-derived loops of the central Alu hairpin, revealing a cross-talk between traditional and auxilliary splicing motifs that evolved from opposite termini of 7SL RNA and were approximated by Watson-Crick base-pairing already in organisms without spliceosomal introns. We also identify existing Alu exons activated by the same RNA rearrangement. Collectively, these results provide valuable TE exon models for studying formation and kinetics of pre-mRNA building blocks required for splice-site selection and will be useful for fine-tuning auxilliary splicing motifs and exon and intron size constraints that govern aberrant splice-site activation.
Keywords: DBASS3; DBASS5; RNA processing; RNA secondary structure; Transposed element; genetic disease; lariat branch point; mutation; splice site.
Conflict of interest statement
None. Inventor royalties from a licensing agreement for the intellectual property unrelated to this work (US patents 9,714,422 and 10,196,639) were personally contributed to the University of Southampton Faculty of Medicine and converted into a research grant administered by the same institution.
Figures

Characteristics of mutation-induced aberrant 3ʹ and 5ʹ splice sites that resulted in genetic disease. (a, b) Total number of cryptic and de novo 5’ss (a) and 3’ss (b) in DBASS. (c) Location of aberrant splice sites. (d, e) Proportion of multiple aberrant 5’ss (d) and 3’ss (e) activated by a single mutation. (f) The intrinsic strength of aberrant 5ʹ and 3’ss and their authentic counterparts. Their numbers are shown in panels (a) and (b). Whiskers/boxes denote quartiles, black lines denote medians. P values for the indicated comparisons of mean ME scores were derived by unpaired t-tests. T-values were 13.01 (5’ss) and 7.85 (3’ss)

Intron and exon size constraints that hold back strong contenders. Location of 92 pairs of strong-cryptic (S) and weak-authentic (W) splice sites in introns (left) and exons (right). Their location is denoted by circles. For each pair, the ME score of cryptic site was higher than for its authentic counterpart (Table S1). Activation of each cryptic site resulted in human genetic disease (Table S1). Introns are denoted by horizontal lines, exons by boxes. WT, MUT; wild-type and mutated splice sites, respectively. Asterisk, mutation; X, splice-site repression; √, splice-site activation. The total number of S-W pairs in each group (N) is shown to the left. The number of aberrant 3’ss (top) or aberrant 5’ss (bottom) with small (≤100 nt) adjacent exons (left) or small (≤200 nt) adjacent introns (right) is in red; their proportions are in parentheses. Size-restricted segments are in orange

New TE clusters as substrates for aberrant splice site activation. (a,b) Mutation-induced exonization of the LTR78-AluJ cluster in F8 intron 18. (a) Schematics of mutation-induced pseudoexon splice sites located in separate TEs. Canonical exons are denoted by black boxes, pseudoexon by a grey box. Exon length is in nucleotides below. A scale at the bottom is in kilobases (kb). Mutation (asterisk) activated the pseudoexon via a de novo 5’ss, leading to mild haemophilia A [62]. Dotted lines above and below the pre-mRNA indicate aberrant and canonical splicing, respectively. (b) Sequences around pseudoexon splice sites. Splice sites are denoted by a slash. A putative branch point adenine in LTR78 (boxed) was predicted by the SVM-BP algorithm [73]; the disease-causing mutation is underlined. Sequences in blue and red are derived from LTR78 and AluJ, respectively. (c,d) Mutation-induced exonization of a LINE and MER58A cluster in COL4A5. (c) Schematics of mutation-induced splice sites activated in separate TEs. For full legend, see panel (a). (d) Sequences around pseudoexon splice sites. Sequences in blue are derived from a LINE-1 copy, sequences in orange from a MER58A copy. Mutation (asterisk) creating the 3’ss AG led to pseudoexon activation, causing Alport syndrome [63]

TEs can contribute only a portion of traditional splicing elements and can be activated by distant mutations. (a,b) A LINE fragment contributing the 5ʹ part of the predicted branch point sequence of the GPR143 pseudoexon. (a) Schematics of the mutation-induced pseudoexon. For full legend, see Figure 3(a). Blue horizontal rectangle denotes the the 3ʹ end of L1MD3. Black arrow denotes BPS. (b) Sequences around pseudoexon splice sites. (c,d) AluY as a source of the BPS, PPT and 3’ss of a CEP290 pseudoexon. (c) Schematics of the mutation-induced pseudoexon. Horizontal red arrow denotes a full-length AluY copy. For full legend, see Fig. 3A. (d) Sequences around pseudoexon splice sites

Structural probing of a composite LTR78/AluJ exon activated in the F8 gene. (a,b) Denaturing polyacrylamide gels with a dideoxynucleoside triphosphate-generated stops (left) run in parallel with primer extension reactions for the WT (a) and mutant (b) F8 probes in the presence (+) and absence (-) of DMS. FL, full-length transcript. Predicted AluJ-derived apical tetraloop/stem is boxed/underlined. (c) Normalized DMS reactivities for WT and mutant F8 RNAs. Columns are means and error bars are SDs, as calculated from 2 independent experiments. Asterisks denote significant decline of DMS reactivities in the mutant (P < 0.05, ANOVA with Tukey’s post-hoc test); negative values were cut off at −2. The mutated residue (F8 c.5998 + 530 C > T) that activated an intronic 5’ss and caused haemophilia [62] is in red. (d) Sequence alignment of the human 7SL RNA gene (RNA7SL1), Repbase AluJb consensus [102] and the exonized left arm of the AluJ copy in F8 intron 18. Three orange dots separate the 5ʹ (1–80) and 3ʹ (262–299) termini of 7SL RNA that gave rise to mammalian free left Alu monomers [30,66]. Conserved adenines with differential DMS reactivities in the exonized left arm of the F8 AluJ are in red. The pseudoexon is highlighted in grey. The exonized left arm of F8 AluJ and corresponding 7SL RNA sequences are ~70% identical

SHAPE reactivities for WT and mutated F8 transcripts. (a) SHAPE gels with NAI-modified WT and mutant RNA probes that visualize their 3ʹ (left panel) and 5ʹ (right panel) portions. (b) Normalized NAI reactivities (upper panel) and PU values (lower panel) for identical RNA segments

Comparison of the secondary structure of 7SL RNA within the Alu domain of SRP and SHAPE-guided structures of WT and mutated LTR78/AluJ RNAs. (a) Secondary structure of 7SL RNA within the Alu domain of SRP [65,66,99]. Helices (H) and loops (L) in orange are numbered according to a previously published topology [99]. The central stem (H3) is also known as helix 5 in the unifying nomenclature of all SRPs (circled) [67], stem V [68] or stem III [65]. Lower case letters indicate RNA sequences that are absent in the left Alu arm consensus [65] (Figure 5(d)). The C > U mutation is denoted by a black arrow. Blue and pink rectangles denote the central stem portions that are most similar to the F8 AluJ structure and were derived from the 5ʹ and 3ʹ parts of 7SL RNA, respectively. Conserved adenines with differential DMS reactivities in WT and mutated F8 probes are in red. (b,c) SHAPE-guided secondary structure of the WT (b) and mutant (c) LTR78/AluJ RNAs. Normalized DMS and NAI reactivities (colour coded as indicated) are shown in Figs. 5 and 6. Black triangles indicate major RNase A cleavage sites (numbered 1–7); their size indicates normalized cleavage intensities in the WT (Fig. S1). In the mutant (c), triangle sizes indicate changes in relative cleavage intensities as compared to the WT; red triangles denote >3-fold differences between the mutant and WT. The linkers and RT primers are highlighted in grey. Alternative structures are shown in Fig. S2. Decoy and active 5’ss are marked by closed and open green triangles, respectively. Secondary structures in panels (b) and (c) were predicted by RNAstructure [103] using normalized NAI constraints and default options. d Alignment of existing sense AluJ exons that employ the same decoy 5’ss as the F8 AluJ copy. The 5’ss are denoted by a slash. Dashes are alignment gaps; three orange dots separate the 5ʹ and 3ʹ parts of 7SL RNA that gave rise to Alu-like elements [30,66]. Full sequences of sense Alus that use 5’ss homologous to that activated in the AluJ copy in F8 are in Table S2. Their alignment is in Figure S3
Similar articles
-
DBASS3 and DBASS5: databases of aberrant 3'- and 5'-splice sites.
Buratti E, Chivers M, Hwang G, Vorechovsky I. Buratti E, et al. Nucleic Acids Res. 2011 Jan;39(Database issue):D86-91. doi: 10.1093/nar/gkq887. Epub 2010 Oct 6. Nucleic Acids Res. 2011. PMID: 20929868 Free PMC article.
-
Transposable elements in disease-associated cryptic exons.
Vorechovsky I. Vorechovsky I. Hum Genet. 2010 Feb;127(2):135-54. doi: 10.1007/s00439-009-0752-4. Epub 2009 Oct 10. Hum Genet. 2010. PMID: 19823873
-
Kralovicova J, Patel A, Searle M, Vorechovsky I. Kralovicova J, et al. RNA Biol. 2015;12(1):54-69. doi: 10.1080/15476286.2015.1017207. RNA Biol. 2015. PMID: 25826413 Free PMC article.
-
Exonization of transposed elements: A challenge and opportunity for evolution.
Schmitz J, Brosius J. Schmitz J, et al. Biochimie. 2011 Nov;93(11):1928-34. doi: 10.1016/j.biochi.2011.07.014. Epub 2011 Jul 26. Biochimie. 2011. PMID: 21787833 Review.
-
Mutations that alter RNA splicing of the human HPRT gene: a review of the spectrum.
O'Neill JP, Rogan PK, Cariello N, Nicklas JA. O'Neill JP, et al. Mutat Res. 1998 Nov;411(3):179-214. doi: 10.1016/s1383-5742(98)00013-1. Mutat Res. 1998. PMID: 9804951 Review.
Cited by
-
Solovyeva AI, Afanasev RV, Popova MA, Enukashvily NI. Solovyeva AI, et al. Curr Issues Mol Biol. 2024 Aug 5;46(8):8576-8599. doi: 10.3390/cimb46080505. Curr Issues Mol Biol. 2024. PMID: 39194722 Free PMC article.
-
Alu RNA fold links splicing with signal recognition particle proteins.
Borovská I, Vořechovský I, Královičová J. Borovská I, et al. Nucleic Acids Res. 2023 Aug 25;51(15):8199-8216. doi: 10.1093/nar/gkad500. Nucleic Acids Res. 2023. PMID: 37309897 Free PMC article.
-
Exonic splicing code and coordination of divalent metals in proteins.
Bakhtiar D, Vondraskova K, Pengelly RJ, Chivers M, Kralovicova J, Vorechovsky I. Bakhtiar D, et al. Nucleic Acids Res. 2024 Feb 9;52(3):1090-1106. doi: 10.1093/nar/gkad1161. Nucleic Acids Res. 2024. PMID: 38055834 Free PMC article.
-
Restriction of an intron size en route to endothermy.
Královičová J, Borovská I, Pengelly R, Lee E, Abaffy P, Šindelka R, Grutzner F, Vořechovský I. Královičová J, et al. Nucleic Acids Res. 2021 Mar 18;49(5):2460-2487. doi: 10.1093/nar/gkab046. Nucleic Acids Res. 2021. PMID: 33550394 Free PMC article.
-
Background splicing as a predictor of aberrant splicing in genetic disease.
Alexieva D, Long Y, Sarkar R, Dhayan H, Bruet E, Winston RM, Vorechovsky I, Castellano L, Dibb NJ. Alexieva D, et al. RNA Biol. 2022;19(1):256-265. doi: 10.1080/15476286.2021.2024031. Epub 2021 Dec 31. RNA Biol. 2022. PMID: 35188075 Free PMC article.
References
-
- Graveley BR. Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 2001;17:100–107. - PubMed
-
- Wahl MC, Will CL, Luhrmann R.. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136:701–718. - PubMed
-
- Wang Z, Rolish ME, Yeo G, et al. Systematic identification and analysis of exonic splicing silencers. Cell. 2004;119:831–845. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
This work was supported by grants from Bloodwise [award 12060] to I.V., VEGA [2/0057/18] to J.K., the Slovak Research and Development Agency [APVV-18-0096] to J.K., and by patent royalties to J.K. and I.V. as declared above.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous